Literature DB >> 25530081

Screening for neuropathic characteristics in failed back surgery syndromes: challenges for guiding treatment.

John D Markman1, Benjamin T Kress, Maria Frazer, Ross Hanson, Victor Kogan, Jason H Huang.   

Abstract

OBJECTIVE: Neuropathic pain screening tools have shown promise in identifying common neuropathic pain characteristics that derive from diverse etiologies (e.g., diabetic peripheral neuropathy, postherpetic neuralgia). However, no prior studies have specifically assessed whether these tools are capable of discerning the underlying pain mechanisms in the vast, heterogeneous group of patients diagnosed with failed back surgery syndrome (FBSS).
DESIGN: In this clinical observational study, two tests for neuropathic pain characteristics, the Douleur Neuropathique en 4 (DN4) and Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) questionnaires, were performed on 43 subjects with FBSS. Subjects underwent physical or neurosensory exam components of the DN4 and LANSS in the region of most severe pain (e.g., axial low back or lower extremities). DN4 and LANSS scores were correlated with clinical history and neurologic exam, pain-related quality of life questionnaires, and compared to an independent assessment of pain distribution.
RESULTS: The presence of neuropathic characteristics, determined by the DN4 (62% sensitivity, 44% specificity), LANSS (38% sensitivity, 75% specificity; cut-offs of 4 and 12, respectively), or their combination (20% sensitivity, 58% specificity) was associated with higher pain intensity as measured by the visual analog scale (DN4 > 4, P = 0.001; LANSS ≥ 12, P = 0.042), modified Brief Pain Inventory-Short Form (DN4 > 4, P = 0.001; LANSS ≥ 12, P = 0.082), and Neuropathic Pain Symptom Inventory (DN4 > 4, P = 0.001; LANSS ≥ 12, P = 0.001), and greater pain-related functional impairment as measured by the Roland-Morris Disability Questionnaire (DN4 > 4, P = 0.006; LANSS ≥ 12, P = 0.018). The percentage of subjects characterized as neuropathic by the DN4 and LANSS lacked concordance (67.4 vs. 25.6), and the distribution of most severe symptoms (i.e., axial vs radicular) did not correlate with subjects determined to have neuropathic pain.
CONCLUSIONS: Unlike other neuropathic syndromes, the neuropathic component of FBSS is less reliably identified by the LANSS and DN4. Wiley Periodicals, Inc.

Entities:  

Keywords:  Chronic Low Back Pain; DN4; FBSS; LANSS; Neuropathic; Radicular; Spine Surgery

Mesh:

Year:  2014        PMID: 25530081     DOI: 10.1111/pme.12612

Source DB:  PubMed          Journal:  Pain Med        ISSN: 1526-2375            Impact factor:   3.750


  9 in total

1.  Nicotine dependence and the International Association for the Study of Pain neuropathic pain grade in patients with chronic low back pain and radicular pain: is there an association?

Authors:  Emanuel Schembri; Victoria Massalha; Karl Spiteri; Liberato Camilleri; Stephen Lungaro-Mifsud
Journal:  Korean J Pain       Date:  2020-10-01

2.  The appropriate management of persisting pain after spine surgery: a European panel study with recommendations based on the RAND/UCLA method.

Authors:  Volker M Tronnier; Sam Eldabe; Jörg Franke; Frank Huygen; Philippe Rigoard; Javier de Andres Ares; Richard Assaker; Alejandro Gomez-Rice; Marco La Grua; Maarten Moens; Lieven Moke; Christophe Perruchoud; Nasir A Quraishi; Dominique A Rothenfluh; Pedram Tabatabaei; Koen Van Boxem; Carmen Vleggeert-Lankamp; Björn Zoëga; Herman J Stoevelaar
Journal:  Eur Spine J       Date:  2018-08-04       Impact factor: 3.134

3.  Agreement Between the Douleur Neuropathique in 4 Questions and Leeds Assessment of Neuropathic Symptoms and Signs Questionnaires to Classify Neuropathic Pain Among Patients with Leprosy.

Authors:  Jamilly C V Santana; Victor S Santos; Ricardo Q Gurgel; Julianne C V Santana; Francisco P Reis; Luis E Cuevas; Vera L C Feitosa
Journal:  Am J Trop Med Hyg       Date:  2016-07-25       Impact factor: 2.345

4.  Research design considerations for randomized controlled trials of spinal cord stimulation for pain: Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials/Institute of Neuromodulation/International Neuromodulation Society recommendations.

Authors:  Nathaniel Katz; Robert H Dworkin; Richard North; Simon Thomson; Sam Eldabe; Salim M Hayek; Brian H Kopell; John Markman; Ali Rezai; Rod S Taylor; Dennis C Turk; Eric Buchser; Howard Fields; Gregory Fiore; McKenzie Ferguson; Jennifer Gewandter; Chris Hilker; Roshini Jain; Angela Leitner; John Loeser; Ewan McNicol; Turo Nurmikko; Jane Shipley; Rahul Singh; Andrea Trescot; Robert van Dongen; Lalit Venkatesan
Journal:  Pain       Date:  2021-07-01       Impact factor: 6.961

5.  Palmitoylethanolamide in the Treatment of Failed Back Surgery Syndrome.

Authors:  Antonella Paladini; Giustino Varrassi; Giuseppe Bentivegna; Sandro Carletti; Alba Piroli; Stefano Coaccioli
Journal:  Pain Res Treat       Date:  2017-08-10

Review 6.  Neuropathic Pain after Spinal Surgery.

Authors:  Jae Hwan Cho; Jae Hyup Lee; Kwang-Sup Song; Jae-Young Hong
Journal:  Asian Spine J       Date:  2017-08-07

7.  Are steroids required in the treatment of ganglion impar blockade in chronic coccydynia? a prospective double-blinded clinical trial.

Authors:  Savas Sencan; Ipek Saadet Edipoglu; Fatma Gul Ulku Demir; Gunay Yolcu; Osman Hakan Gunduz
Journal:  Korean J Pain       Date:  2019-10-01

8.  Investigating the validity of the DN4 in a consecutive population of patients with chronic pain.

Authors:  Hans Timmerman; Monique A H Steegers; Frank J P M Huygen; Jelle J Goeman; Nick T van Dasselaar; Marcel J Schenkels; Oliver H G Wilder-Smith; André P Wolff; Kris C P Vissers
Journal:  PLoS One       Date:  2017-11-30       Impact factor: 3.240

9.  Evaluation of pulsed electromagnetic field therapy for the treatment of chronic postoperative pain following lumbar surgery: a pilot, double-blind, randomized, sham-controlled clinical trial.

Authors:  Robert Gordon Sorrell; Jamie Muhlenfeld; John Moffett; Gary Stevens; Steven Kesten
Journal:  J Pain Res       Date:  2018-06-22       Impact factor: 3.133

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.